Lenalidomide Qilu

Lenalidomide, the active ingredient in Lenalidomide Qilu, is an immunomodulatory agent presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes in adult patients.

GNH USA supplies Lenalidomide Qilu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics across multiple regions. The company adheres to stringent manufacturing standards and provides comprehensive support for product registration and post‑marketing surveillance.

Lenalidomide is an immunomodulatory antineoplastic used in hematologic malignancies and related bone‑marrow disorders. - Multiple myeloma: improves progression‑free survival and overall response rates in adult patients. - Relapsed/refractory multiple myeloma: provides a therapeutic option after prior therapies. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission.

Common Side Effects: - Neutropenia: decreased neutrophil count increasing infection risk. - Thrombocytopenia: reduced platelet levels that may cause bleeding. - Fatigue: persistent tiredness affecting daily activities. - Constipation: difficulty passing stool. - Rash: mild skin irritation or erythema. - Nausea: upset stomach and possible vomiting.

Serious or Rare Side Effects: - Venous thromboembolism: formation of blood clots in veins. - Severe neutropenia: markedly low neutrophil counts leading to serious infections. - Severe infections: opportunistic or bacterial infections requiring hospitalization. - Second primary malignancies: emergence of new cancers unrelated to the original disease. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances. - Hypersensitivity reactions: severe allergic responses including anaphylaxis.

Before initiating therapy, consider the following precautions: - Dose adjustment in renal impairment: assess renal function and modify dose accordingly. - Monitor blood counts regularly: watch for neutropenia, thrombocytopenia, and anemia. - Assess thrombotic risk: consider prophylactic anticoagulation in high‑risk patients. - Avoid use in pregnancy: teratogenic potential requires strict contraception. - Store at ambient temperature: keep below 25 °C, protect from moisture in original packaging.

Lenalidomide may interact with several drug classes. Review patient medication lists carefully. Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce lenalidomide exposure and efficacy. - Anticoagulants: increased risk of bleeding when combined. - Live vaccines: heightened infection risk due to immunosuppression. Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors: may increase plasma concentrations of lenalidomide. - Other immunosuppressants: additive myelosuppression potential. - Hormonal contraceptives: may reduce contraceptive effectiveness, requiring additional barrier methods.